Gain CME accreditation through specific modules offered in this section, explore the Knowledge Exam and books that will assist in your learning journey
Initial Results from a Phase 1 Single Ascending Dose Clinical Trial of STAR-0215, an Investigational Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for Hereditary Angioedema (HAE), in Healthy Subjects Followed for at Least 3 Months
Results From a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial Evaluating Sebetralstat Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability in Healthy Japanese, Chinese, and White Adults
Design of ALPHA-STAR, a Phase 1b/2 Proof-of-Concept Trial of STAR-0215 as a Long-Active Preventative Therapy in Patients with Hereditary Angioedema (HAE) Types I or